Relevant Articles About DLBCL (Diffuse Large B Cell Lymphoma)
Lymphoma Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
KEY TAKEAWAYS The phase 1 trial aimed to investigate the synergistic antitumor effects of HC-7366 and belzutifan in pts with advanced RCC. Researchers concluded that the combination of HC-7366 and belzutifan demonstrates promising antitumor activity in relapsed...
KEY TAKEAWAYS The ARC-14, ARC-28, & ARC-20 phase 1 trial aimed to investigate the relationship between casdatifan dose, PK, EPO levels, and hemoglobin to guide future clinical dose selection. Researchers noticed that a 20 mg daily dose of casdatifan effectively...
KEY TAKEAWAYS The study aimed to evaluate the efficacy of a multiparametric ultrasound imaging omics model for predicting BC recurrence risk and molecular subtyping. Multiparametric ultrasound imaging omics predicted BC recurrence and molecular typing, guiding...
The Smart Stop phase 2 study aimed to investigate the efficacy of reducing or omitting CIT cycles after a positive response to targeted …
The phase 2 study aimed to investigate the efficacy of early intervention with Glofitamab plus R-CHOP in improving outcomes for previously untreated high-risk …
The phase 1 & 2 trial aimed to assess the preliminary efficacy and safety of M-Pola in elderly, U/F pts with newly diagnosed …
Background Melanoma, the most lethal form of skin cancer, has undergone a transformative treatment shift with the advent of checkpoint blockade immunotherapy (CBI). Understanding the intricate network of immune cells infiltrating the tumor and orchestrating the …
Background Immune-related hepatitis (irHepatitis) is a relatively common immune-related adverse event (irAE) of checkpoint inhibitors. Often, it responds well to steroids; however, in refractory cases, further therapy is needed. Anti-tumor necrosis factor (TNF) antibodies are used …
Objectives: Disparities exist in the length and quality of survival from melanoma. This study evaluated, in a Texas cohort, patient factors associated with melanoma survival and examined if newer immune-oncologic agents extend survival compared with …